According to the World Health Organization, 63% of the 57 million deaths in 2008 were due to noncommunicable diseases [1] . Of these, cardiovascular (CV) diseases were the most common, accounting for approximately 30% of all deaths globally, followed by cancers (13%), chronic lung diseases (7%) and diabetes (2%). Whilst noncommunicable disease mortality rates have fallen in the developed world during recent years, rates continue to increase in lower income populations, with approximately 80% of all noncommu ni cable disease deaths occurring in low-income and middle-income countries. Of these deaths, 29% occur in people under the age of 60 years.
mass index. Rather than existing in isolation, these risk factors tend to occur in clusters [3] . Data from the National Health and Nutrition Examination Survey (1999 to 2000) showed that 93.1%, 73.0%, and 35.9% of US adults had ≥1, ≥2, and ≥3 modifi able risk factors for CV disease, respectively [4] . Since each additional risk factor has a multiplicative, rather than an additive, eff ect on vascular risk [5] , patients with clusters of risk factors have a signifi cantly increased risk of developing CV and cerebrovascular disease. Metabolic syndrome (MetS), for example -charac ter ized by three or more of the following: abdominal obesity, atherogenic dyslipidemia, hypertension, and/or insulin resistance with or without glucose intolerance [6] [7] [8] [9] [10] -is associated with a twofold to fourfold increased risk of stroke, a threefold to fourfold increased risk of myocardial infarction [11, 12] , and a fi vefold to ninefold higher risk of developing type 2 diabetes (T2D) [13] . Similarly, T2D is associated with a twofold to fourfold increased risk of CV death [14] . Given that many CV risk factors are silent, patients with individual risk factors should be assessed for their overall cardiometabolic profi le and treated accordingly.
Th e recommended treatment for MetS is lifestyle change, focusing on weight loss and physical activity, followed by pharmaceutical treatment for the individual risk factors [6, [8] [9] [10] . Dyslipidemia -an imbalance between the proatherogenic apolipoprotein-B-containing lipoproteins (low-density lipoproteins, very-low density lipoproteins and chylomicrons/chylomicron remnants) and anti-atherogenic high-density lipoproteins (HDLs)is a major risk factor for CV and cerebrovascular disease [5, 15] . Numerous studies show that lowering low-density lipoprotein-cholesterol (LDL-C) levels using statins can signifi cantly reduce CV risk in people with and without T2D, with no lower limit beyond which LDL-C-lowering is not benefi cial [16] [17] [18] [19] [20] [21] [22] [23] . Based on these results, most international treatment guidelines recommend lowering LDL-C to <2.6 mmol/l (100 mg/dl) in patients with established CV disease and to <1.8 to 2.0 mmol/l (70 to 80 mg/dl) in those with very high CV risk, reducing total cholesterol to <4.5 mmol/l (174 mg/dl) with an option of <4 mmol/l (154 mg/dl) if feasible [6, 9, [24] [25] [26] . Although most statins (including atorvastatin, simvastatin and pitavastatin) have similar eff ects on LDL-C levels [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , diff er ences in chemical structure and pharmacokinetic profi le can lead to variations in pleiotropic eff ects, adverse event profi les and drug-drug interactions. Th e choice of statin should therefore depend on the characteristics and needs of the individual patient.
Despite the widespread availability of eff ective lipidlowering drugs, the prevalence of hypercholesterolemia varies considerably throughout Europe, ranging from 3 to 53% in men and from 4 to 40% in women, depending on the country [38] . In most populations, almost 50% of people treated with lipid-lowering drugs have a total cholesterol level >6.5 mmol/l (251 mg/dl), suggesting that greater eff orts are needed to identify and adequately treat people with hypercholesterolemia. Moreover, even in patients that fully attain their total cholesterol/LDL-C targets, the risk of major vascular events is only reduced by around one-third [17] , leaving substantial residual risk. Th e identifi cation and treatment of residual risk factors is therefore essential for the eff ective management of CV disease.
The importance of high-density lipoprotein for reducing residual risk
Numerous studies have shown that low levels of highdensity lipoprotein-cholesterol (HDL-C) (defi ned as <1 mmol/l; 40 mg/dl in men, and <1.3 mmol/l; 50 mg/dl in women) are independent risk factors for coronary heart disease [39] [40] [41] [42] [43] [44] [45] [46] . Th e Emerging Risk Factors Collaboration analyzed records from 68 studies in 302,430 people without initial vascular disease and demonstrated that each 0.38 mmol/l (14 mg/dl) increase in HDL-C level was associated with a 22% reduction in coronary heart disease risk, irrespective of the triglyceride (TG) level ( Figure 1 ) [42] . Consequently, the recent European Society of Cardiology/European Athero scler osis Society Guidelines for the Management of Dyslipid emia have included low HDL-C levels in their latest CV risk assessment charts [6, 9, 39] . Th is is particularly important for people with MetS or T2D who often have low levels of HDL-C accompanied by high levels of TG (≥1.7 mmol/l; 150 mg/dl) and a preponderance of small, dense lowdensity lipoprotein particles that can result in an underestimation of risk based solely on LDL-C. Th is triad of lipid abnormalities has been called atherogenic dyslipidemia [47] [48] [49] .
A number of therapeutic options are available for increasing HDL-C levels, including statins, fi brates and niacin [6, 39] . In general, niacin can increase HDL-C by 10 to 25%. However, recent results from the AIM-HIGH and HPS-2 THRIVE studies showed that the additional increases in HDL-C achieved when extended-release niacin was added to a statin did not result in further reductions in CV events [50, 51] . Fibrates, on the contrary, can increase HDL levels by 2 to 10% and have been shown to reduce CV risk in people with signifi cantly elevated levels of TG and reduced levels of HDL-C [52] [53] [54] [55] . For example, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study found that the primary event rate (a composite of nonfatal myocardial infarction, stroke or CV death) was reduced from 17.3% to 12.4% in the subgroup of T2D patients with both low baseline levels of HDL-C (≤34 mg/dl or 0.88 mol/l) and high baseline TG (≥204 mg/dl or ≥2.3 mmol/l) [52] . However, this study also showed that the addition of fenofi brate to conventional statin treatment had no eff ect on event rates in people with normal levels of TG and/or HDL-C.
To date, the only lipid-lowering studies in which druginduced elevations in HDL-C have been found to correlate with reductions in CV risk involve statins [56] [57] [58] [59] [60] . A post hoc analysis of the Treating to New Targets (TNT) trial conducted in 2,661 subjects achieving LDL-C <1.8 mmol/l (70 mg/dl) during treatment with atorvastatin 10 or 80 mg/day showed that HDL-C levels were predictive of major CV events across the entire cohort, both when HDL-C was considered a continuous variable and when subjects were stratifi ed according to HDL-C quintile [56] . Th is relationship remained true even after event rates were adjusted for other risk factors, including baseline levels of LDL-C ( Figure 2) . Consistent with this observation, a post hoc analysis of intravascular ultrasound data from 1,455 people in four prospective randomized clinical trials showed that statinassociated changes in HDL-C were inversely associated with the progression of coronary atherosclerosis even in patients with low levels of LDL-C [61] . Th e proposed explanation for these fi ndings is that statin-induced HDL elevations stimulate the 'reverse cholesterol transport' pathway, a process in which excess cholesterol is removed from peripheral cells and transported to the liver via HDL for excretion into bile [49] . Although most statins increase HDL-C levels to some extent, pitavastatin consistently produces signifi cantly greater HDL elevations that are maintained, or increased, over time [29, 58, 60, [62] [63] [64] . Pitavastatin is therefore likely to be particularly effi cacious in people with low levels of HDL-C, such as those with cardiometabolic disease.
In addition to their role in cholesterol homeostasis, HDL particles have been shown to reduce oxidation, reduce vascular infl ammation and vascular thrombosis, to improve endothelial function and repair, and to regulate the function and survival of pancreatic β-cells [47, 49, 65] . Th ese functions are often defective in patients with infl ammatory conditions such as MetS and T2D and can add to a patient's overall CV risk. Recent studies have shown that, in addition to elevating HDL levels, some lipid-lowering agents are associated with pleiotropic eff ects that improve HDL structure and function [47, 49, [66] [67] [68] . Th is observation is supported by a recent study, in which pitavastatin was associated with significantly greater reductions in plaque volume per 1% increase in HDL-C than other statins (atorvastatin, pravastatin, rosuvastatin, simvastatin) [67] . Future studies should therefore assess the eff ects of statins on HDL quality as well as quantity.
Th e following reviews will discuss the potential benefi ts of pitavastatin versus other statins in the treatment of patients with dyslipidemia, MetS or T2D, focusing on its eff ects on HDL-C quantity and quality, its impact on atherosclerosis and CV risk, and the avoidance of drug interactions. Recent controversies surrounding the potentially diabetogenic eff ects of statins will also be discussed, with a focus on the possibility that pitavastatin diff ers positively from other statins in this regard. Abbreviations CV, cardiovascular; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; MetS, metabolic syndrome; T2D, type 2 diabetes; TG, triglyceride.
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